Inhibrx Biosciences, Inc.: Business Overview, Financials & Competitive Analysis
Inhibrx Biosciences, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Clinical-stage biotech with first-to-market potential in orphan oncology indications backed by proprietary protein engineering platform; execution on Phase 2/3 trials is key catalyst. Early-stage biotech with compelling clinical pipeline showing positive efficacy signals, particularly ozekibart meeting primary endpoints in registrational trials. However, pre-revenue status, recent 2024 founding, and typical.
What is Inhibrx Biosciences, Inc.'s industry? Inhibrx Biosciences, Inc. (inhibrx.com) operates in Biopharmaceutical/Oncology Therapeutics. AskCyborg classifies Inhibrx Biosciences, Inc. under Biopharmaceutical/Oncology Therapeutics in its company registry.
Inhibrx Biosciences is a clinical-stage biopharmaceutical company developing a broad pipeline of novel biologic therapeutic candidates using diverse protein engineering methods. The company's pipeline includes INBRX-1...
Cyborg Score thesis
Clinical-stage biotech with first-to-market potential in orphan oncology indications backed by proprietary protein engineering...
Read the full analyst-debate transcript →Get the Latest Inhibrx Biosciences, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeInhibrx Biosciences, Inc. Overview
Pro stress-test →Inhibrx Biosciences is a clinical-stage biopharmaceutical company developing a broad pipeline of novel biologic therapeutic candidates using diverse protein engineering methods. The company's pipeline includes INBRX-109, a tetravalent therapeutic targeting death-receptor 5 for chondrosarcoma, and INBRX-106, a hexavalent sdAb-based therapeutic targeting OX40 for multiple solid tumor indications.
Strategic Profile
Pro stress-test →Founded in 2024 and based in La Jolla, California, Inhibrx leverages proprietary modular protein engineering platforms to develop targeted cancer therapeutics. The company's lead candidate ozekibart (INBRX-109) represents potential first-in-class therapy for chondrosarcoma, positioning Inhibrx at the forefront of precision oncology with near-term regulatory catalysts.
Competitive Landscape
Pro stress-test →Inhibrx competes with biotech firms including Harbour BioMed, NGM Bio, Allakos, and Allogene Therapeutics. The company differentiates through its proprietary protein engineering platform enabling optimized multivalent formats and focus on underdeveloped oncology indications like chondrosarcoma where unmet medical need is substantial.
Industry Context
Inhibrx Biosciences, Inc. operates in Biopharmaceutical/Oncology Therapeutics.
Key facts
Founded: 2024 · Headquarters: La Jolla, US · Employees: 161 · Market cap: $166M